Managing IP hosted the inaugural MIP Life Sciences Forum 2016 in New York on September 14.Over the past year IP owners in the life sciences sector have been facing uniqueopportunities and challenges when protecting their patents. Rapid developments inthe landscape of drug discovery, research and pending proposals for reform inCongress means that your strategies to protect your IP may need rethinking.As such, the Forum tracked legislative developments within the life sciences sector, examined the potential impact and forecasted one, five and 10-year horizon for changes. In addition, the Forum addressed:
Senior IP and general counsel from leading pharmaceutical and life sciences organisations shared their experiences of managing IP matters and engaged in lively debate on all the pertinent topics within life sciences from varied perspectives. EVENT FEEDBACK"Well qualified speakers, latest perspectives, great forum in an intimate environment""Highly practical information, insights and analysis!"The conference was very high quality and the speakers were very knowledgeable. I like that they pointed out practice tips and tried to predict where the law might go.""The topics were ideal for the issues facing the protection of biotech IP""Thank you for the invitation to attend this. It really was a first-rate event."Key takeaways from the event will be made available shortly and you can view photos from the event here.To receive advance notice for the next year's event, email email@example.com
European Commission approves Qualcomm's acquisition of NXP, subject to conditions https://t.co/0LQaJUbYmm Qualcomm… https://t.co/sk8YHNFZny
easyGroup loses trade mark fight against EasyRoommate https://t.co/RbXV5TJ8Cn Property letting business doesn't inf… https://t.co/gPvR1fnvdP
RT @business: Google and Tencent have agreed to share patents https://t.co/QmS9nhkf3Y https://t.co/lc3lFOo9EF
End of Year 2017
Tribal sovereign immunity: Taking a wrecking ball to the IPR system
The lawyer behind Allergan’s controversial transfer of patents to a Native American tribe says others are “lining up to do deals”. But, Michael Loney asks, will the PTAB rule that sovereign immunity applies in these types of deals?
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2018 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International